Market Intelligence, Clinical Progress, and High-Purity Reagents for RAS-Driven Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SOS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOS1 Recombinant Protein (Rem-CDC25 Catalytic Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Ideal for nucleotide exchange assays. |
View SOS1 Products |
| Gene Delivery | SOS1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling pathway validation. |
View SOS1 Products |
| Benchmark Ab | Anti-SOS1 Recombinant Antibody Recombinant positive control for Western Blot, IP, and intracellular localization. |
View SOS1 Products |
| Validator | SOS1 siRNA Set For target knockdown verification and target validation in KRAS-mutant cells. |
View SOS1 Products |
| Related Target A | KRAS (Mutants G12D, G12C, G12V) Synergistic pathway partner. Crucial for SOS1-mediated nucleotide exchange assays. |
View KRAS Products |
| Related Target B | SHP2 (PTPN11) Upstream regulator in the RTK-RAS pathway. Key target for combination therapy screening. |
View SHP2 Products |
| Related Target C | EGFR (WT & Mutants) Feedback loop activator. Essential for resistance bypass mechanism studies. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Assaying SOS1-mediated nucleotide exchange | High-purity SOS1 catalytic domain (Rem-CDC25) and nucleotide-free KRAS proteins available with strictly controlled activity. |
| SOS1 vs. SOS2 subfamily counter-screening | Homolog panel proteins (recombinant SOS2) verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of reliable intracellular controls | Sequence-verified benchmark antibodies and validated siRNA sets included for phenotypic assay normalization. |
| False positives in high-throughput screening (HTS) | Endotoxin-controlled, high-purity proteins reduce non-specific binding in microplate-based assays. |
Live SOS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SOS1 therapeutics is intensifying, with major players shifting focus from monotherapy to rational combination regimens. As first-generation SOS1 inhibitors (such as BI-1701963 and MRTX0902) progress through clinical trials, the next wave of R&D is targeting the circumvention of adaptive resistance in KRAS-mutant solid tumors. By disrupting the SOS1-RAS interaction, these therapies prevent the reactivation of wild-type RAS isoforms (KRAS, HRAS, NRAS) triggered by upstream receptor tyrosine kinase (RTK) feedback loops.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Boehringer Ingelheim, Mirati Therapeutics (BMS), Bayer | KRAS-mutant CRC, NSCLC, Pancreatic Cancer | Nucleotide Exchange Assay (Need high-purity catalytic domain and mutant KRAS) |
| PROTACs / Degraders | Academic institutions, Biotech startups | Advanced Solid Tumors with RAS alterations | Ternary Complex Formation (Need stable, sequence-verified SOS1 and E3 ligase proteins) |
| Combination Therapies | Amgen, Mirati, Novartis | Refractory KRAS G12C/G12D cancers | Synergy Screening (Need assay-ready lentivirus and siRNA for validation) |